Investigational drug for metastatic pancreatic ductal adenocarcinoma

Trial ID:
IRB-25-8686
Darren Sigal, M.D.

Inclusion Criteria

Patients must:

  • Be 18 years of age or older
  • Have histologically or cytologically confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma
  • Have homozygous MTAP deletion or MTAP loss detected in tumor tissue

Exclusion Criteria

Patients must not:

  • Have received any systemic anticancer treatments in the metastatic setting
  • Be pregnant, breastfeeding, or planning to conceive during the study
  • Have had a prior organ allograft
  • Have uncontrolled/symptomatic or significant cardiovascular conditions within 6 months prior to study treatment

Additional Info

This is a blinded study which means the participant, study team, and physician will not know if the participant will receive BMS-986504 or placebo.

All treatments and physician visits will take place at Scripps Clinic Torrey Pines.

For more information, search NCT07076121 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org